PT PHAPROS TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 410 IDR | -6.82% |
|
-15.29% | -35.94% |
| Apr. 06 | PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | PT Phapros, Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 1,168B 72.45M | Sales 2023 | 1,014B 62.88M | Capitalization | 538B 33.33M |
|---|---|---|---|---|---|
| Net income 2022 | 28.07B 1.74M | Net income 2023 | 5.96B 369K | EV / Sales 2022 | 1.09 x |
| Net Debt 2022 | 696B 43.14M | Net Debt 2023 | 737B 45.68M | EV / Sales 2023 | 1.26 x |
| P/E ratio 2022 |
20.5
x | P/E ratio 2023 |
90.2
x | Employees | 1,474 |
| Yield 2022 |
1.95% | Yield 2023 |
-
| Free-Float | 13.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -6.82% | ||
| 1 week | -15.29% | ||
| Current month | -7.24% | ||
| 1 month | -17.67% | ||
| 3 months | -21.15% | ||
| 6 months | -26.79% | ||
| Current year | -35.94% |
1 week
410.00
492.00
1 month
410.00525.00
Current year
410.00665.00
1 year
410.001 000.00
3 years
410.001 550.00
5 years
410.002 970.00
10 years
410.003 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Sidjabat
CEO | Chief Executive Officer | - | 21-05-26 |
| Chief Tech/Sci/R&D Officer | - | - | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 08-03-31 | |
| Director/Board Member | 51 | 21-05-26 | |
| Chairman | - | 21-05-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 410 | -6.82% | 370,400 |
| 24-06-03 | 440 | -0.45% | 164,000 |
| 24-05-31 | 442 | -0.90% | 156,900 |
| 24-05-30 | 446 | -8.23% | 1,279,300 |
| 24-05-29 | 486 | -0.41% | 131,500 |
End-of-day quote INDONESIA S.E., June 03, 2024
More quotes
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -35.94% | 22.77M | |
| +42.83% | 748B | |
| +34.11% | 598B | |
| -5.70% | 356B | |
| +18.06% | 325B | |
| +4.63% | 283B | |
| +17.02% | 245B | |
| +9.26% | 211B | |
| -4.21% | 209B | |
| +2.43% | 166B |
- Stock Market
- Equities
- PEHA Stock
